Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06010342 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
A Phase 2 study of Solid Tumor, sponsored by Teligene US.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 19
- Study locations
NCT06010342: Recruiting Phase 2 study of Solid Tumor, sponsored by Teligene US.
NCT06010342 is a Phase 2 study of Solid Tumor that is actively recruiting participants, run by Teligene US. The registered enrollment target is 60 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (73% lower). The trial reports 19 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06010342, a Phase 2 study of Solid Tumor, is actively recruiting participants, sponsored by Teligene US.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 19
- Study locations
Study Summary
The main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions
Conditions Studied
Interventions
- DRUG TL118 Capsule
Study Locations (19)
Texas
- Texas Oncology - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
Beijing Municipality
- Beijing Cancer Hospital - Beijing
- Peking University School and Hospital of Stomatology - Beijing
California
- Adventist Health Glendale - Glendale
Chongqing Municipality
- Chongqing University Cancer Hospital - Chongqing
Fujian
- Fujian Cancer Hospital - Fuzhou
Guangdong
- Affiliated Cancer Hospital and Institute of Guangzhou Medical University - Guangzhou
Heilongjiang
- Harbin medical university cancer hospital - Harbin
Henan
- The First Affiliated Hospital of Zhengzhou University - Zhengzhou
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-03-16 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 2 |
What NCT06010342 shows while recruiting
NCT06010342 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which TL118 Capsule is the first listed.
NCT06010342 lists 19 locations in 17 states (Texas, Beijing Municipality, California).
Frequently Asked Questions
What is clinical trial NCT06010342 about?
NCT06010342 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients". The main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions
What is the current status of trial NCT06010342?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-03-16. Estimated completion is 2027-04-30.
What conditions does trial NCT06010342 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT06010342?
The interventions under investigation include: TL118 Capsule (DRUG).
Who is sponsoring clinical trial NCT06010342?
This trial is sponsored by Teligene US, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06010342 being conducted?
This trial has 19 study locations across California, Texas, Beijing Municipality, Chongqing Municipality, Fujian. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06010342's enrollment target sits among peer trials
60 110th of 196 higher than 85 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
RECRUITING · Phase 2
-
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
RECRUITING · Phase 2
-
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI